#NANETS2024

We’re glad you liked #nanets2024 !

@nanets.bsky.social will be sending out an email in the coming weeks with info for signing up to different committees.

We would love to have you on board! I’m more than happy to help guide you through the process if needed 😊

I had an honestly inspiring experience at #NANETS2024 @nanets.bsky.social filled with great networking and confidence building from mentors. I’ve written goals, but any tips on keeping up that post-conference momentum? Especially heading into the holiday season work hiatus?

Our Keynote session with Dr Charles Swanton was just WOW!!! 🤩🤩🤩
Day3 #nanets2024 @nanets.bsky.social

On day 2 of #NANETS2024 I think it's a good time to do a first look at placebo in clinical trials. This is a contentious topic that I'll try to approach with sensitivity and answer two questions:
1. What is a placebo?
2. Why do we use it in clinical trials?

#OncSky #MedSky

Thanks @nanets.bsky.social team for the impeccable planning!!! #nanets2024 exciting Day 2 !!!

Pivotal phase III COMPOSE trial will compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors. | Journal... TPS514Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which represent approximately 70% of NETs, frequently develop metastatic disease with limited treatment options. Current stan...

In summary: we should strongly consider Lutathera + SSRT over SSRT alone in our grade 2 NET patients. However, for grade 3 patients, I eagerly await the results of the Phase 3 COMPOSE trial before changing my practice entirely. ascopubs.org/doi/10.1200/...
#oncsky #NETsky #NANETS2024

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendoc... First-line 177Lu-Dotatate plus octreotide LAR significantly extended median progression-free survival (by 14 months) in patients with grade 2 or 3 advanced gastroenteropancreatic neuroendocrine tumour...

As we begin #NANETS2024 it may be a good time to review why the NETTER-2 study represents a promising advance in our understanding of NET tumor management.
#oncsky

www.thelancet.com/journals/lan...

Right on time for #NANETS2024: the North American Neuroendocrine Tumor Society is on @bsky.app ! Lots of posts to come from the NET community over the next three days during the Annual Symposium taking place in #Chicago. @oncothor.bsky.social @cancertrials.bsky.social @halletjulie.bsky.social